To find out more about current Genetics studies you can view a list of studies on the NIHR Clinical Research Network Portfolio Database
The NIHR Clinical Research Network Cancer has been enormously successful in integrating clinical research into NHS clinical service provision, and both developing and delivering a large practice changing portfolio of clinical trials.
View our Genetics specialty profile to find out more.
The genetics specialty has supported a number of major studies and is there to support the clinical teams throughout the study process. The following are some key examples of the studies that the Specialty has helped promote and support:
In the UK, asthma affects around five million people. A child is admitted to hospital every 18 minutes due to their asthma. The Genetics Specialty is currently supporting The Personalised medicine for Asthma ConTrol (PACT) study led by Professor Somnath Mukhopadhyay, Brighton and Sussex Medical School, and the Royal Alexandra Children’s Hospital. This study is investigating whether prescribing medication according to a child’s genetic makeup could lead to better control of a their asthma.
Every year, thousands of babies are born in the UK who do not develop normally because of errors in their genetic makeup. Currently, diagnosis is restricted to a small minority; upto half of children with severe developmental disorders of probable genetic origin remain without a diagnosis. The aim of the Deciphering Developmental Disorders Study (DDD) is to determine if new high-throughput genetic technologies can determine the cause of developmental disorders, and to facilitate the use of these technologies in the NHS. Analysis is ongoing, but to date the team have achieve a diagnostic rate of ~35% in patients where previous genetic investigations had failed to identify a diagnosis. So far, more than 30 new developmental disorder genes have been identified as a result of this study.
The NIHR UK Rare Genetic Disease Research Consortium Agreement, also known as the Musketeers’ Memorandum was agreed in 2013. This allows a single lead UK genetics unit to rapidly enable set-up for a rare disease non-CTIMP (Clinical Trial of an Investigational Medicinal Product) project, which can then be delivered across all regional genetics centres. This has enabled national involvement in over 30 studies that might not otherwise have been able to recruit adequate numbers of patients. It also enables fair and even access to patients with rare disease across the UK. The Memorandum is included in the UK rare disease strategy.
If you think your study might benefit from the Musketeers’ Memorandum, please view the Musketeers’ Memorandum webpage for more information, including eligibility criteria and contact details.